Personalized approaches to the treatment of hemostatic disorders

The last 20 years has seen dramatic improvements in the clinical management of hemostatic and thrombotic disorders. We have witnessed the introduction of novel therapeutic agents into the clinic, including direct oral anticoagulants (DOACs), and the rapid evolution of personalized therapy for patients with the development of high-throughput genetic analysis and gene therapy. Moreover, growing awareness of nonlinear genotype-phenotype correlations in disease presentation, including bleeding or thrombosis risk, has catalyzed the concept of tailored individualized therapies. Many of these clinical milestones have been made possible by improved understanding of the fundamental biology and thus pathophysiology underpinning hemostatic disorders, as well as development of novel technologies and diagnostic tools. This review series aims to provide an overview of some of these advancements, with a particular focus on novel and personalized approaches to the management of disorders of hemostasis and thrombosis.